Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12320895 | 0.98 | CA1 (0.65) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL12310187 | 0.98 | CA1 (0.65) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL29131409 | 0.90 | CA1 (0.65) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL3632654 | 0.90 | CA1 (0.65) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL1343465 | 0.89 | CA1 (0.69) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL13037656 | 0.89 | CA2 (0.55) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL28174467 | 0.87 | CA1 (0.50) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL12320904 | 0.87 | CA2 (0.53) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL12310183 | 0.87 | CA2 (0.53) | CA1CA2CYP1B1CYP1A2CYP1A1 | |
| SCHEMBL17489608 | 0.86 | CA1 (0.56) | CA1CA2CYP1B1CYP1A2CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066397-A | Compounds comprising anti-inflammatory pharmacophores and methods of use | REATA PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | claimed |
| US-7166593-B2 | Glucocorticoid receptor modulators | PFIZER, INC. (US) | 2007-01-23 | — | — | US | claimed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | claimed |
| US-6699893-B2 | DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS | PFIZER INC | 2004-03-02 | — | — | US | claimed |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | HAMANAKA ERNEST S (US) | 2003-10-23 | — | — | US | claimed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | claimed |
| EP-1175383-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | claimed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | claimed |
| WO-2000066522-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | claimed |
| CN-118772223-A | Compositions and methods for treating central nervous system disorders | 萨奇治疗股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-111741965-B | Compositions and methods for treating central nervous system disorders | 萨奇治疗股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023280246-A1 | ORGANIC COMPOUND AND APPLICATION THEREOF IN ORGANIC ELECTRONIC DEVICE | 浙江光昊光电科技有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2021135841-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND AROMATIC COMPOUND CONTAINING FUSED-RING | 广州华睿光电材料有限公司 | 2021-07-08 | — | — | WO | disclosed |
| CN-110003203-A | A kind of method of synthesis 2- acetyl group -1,10- ferrosin (3) | 北京燕联化工技术有限公司 | 2019-07-12 | — | — | CN | disclosed |
| US-6589947-B1 | Treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist. | PFIZER INC. | 2003-07-08 | — | — | US | disclosed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | disclosed |
| US-6380223-B1 | FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
| EP-1175383-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| EP-1097709-A2 | Use of corticotropin releasing factor antagonists for treating syndrome X | Pfizer Products Inc. (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000066522-A1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176595-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | CA1 4667/4885CA2 3983/4885CYP1B1 497/4885 |
| US-20020147336-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | CA1 4665/4885CA2 4001/4885CYP1B1 496/4885 |
| US-20030199527-A1 | Use of corticotropin releasing factor antagonists and related compositions | CRH, CRHR1, CRHR2 | CA1 1012/4885CA2 1316/4885CYP1B1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.